Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

292 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
International multicenter study comparing COVID-19 in patients with cancer to patients without cancer: Impact of risk factors and treatment modalities on survivorship.
Raad II, Hachem R, Masayuki N, Datoguia T, Dagher H, Jiang Y, Subbiah V, Siddiqui B, Bayle A, Somer R, Fernández Cruz A, Gorak E, Bhinder A, Mori N, Hamerschlak N, Shelanski S, Dragovich T, Vong Kiat YE, Fakhreddine S, Pierre AH, Chemaly RF, Mulanovich V, Adachi J, Borjan J, Khawaja F, Granwehr B, John T, Yepez EY, Torres HA, Ammakkanavar NR, Yibirin M, Reyes-Gibby CC, Pande M, Ali N, Rojo RD, Ali SM, Deeba RE, Chaftari P, Matsuo T, Ishikawa K, Hasegawa R, Aguado-Noya R, García AG, Puchol CT, Lee DG, Slavin M, Teh B, Arias CA; Data-Driven Determinants for COVID-19 Oncology Discovery Effort (D3CODE) Team; Kontoyiannis DP, Malek AE, Chaftari AM. Raad II, et al. Among authors: siddiqui b. Elife. 2023 Jan 30;12:e81127. doi: 10.7554/eLife.81127. Elife. 2023. PMID: 36715684 Free PMC article.
Impact of Selective Immunosuppressive Therapy on Subsequent Immune-Related Adverse Events After Immune Checkpoint Inhibitor-Induced Colitis Treatment.
Pizuorno Machado A, Shatila M, Glitza Oliva IC, Altan M, Siddiqui B, Zhou Y, Varatharajalu K, Zhang HC, Thomas A, Wang Y. Pizuorno Machado A, et al. Among authors: siddiqui b. Am J Clin Oncol. 2023 Aug 1;46(8):360-365. doi: 10.1097/COC.0000000000001016. Epub 2023 May 23. Am J Clin Oncol. 2023. PMID: 37219360
Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis.
Siddiqui BA, Palaskas NL, Basu S, Dai Y, He Z, Yadav SS, Allison JP, Sheth RA, Tummala S, Buja M, Bhattacharjee MB, Iliescu C, Rawther-Karedath A, Deswal A, Wang L, Sharma P, Subudhi SK. Siddiqui BA, et al. Cancer Immunol Res. 2024 Aug 1;12(8):964-987. doi: 10.1158/2326-6066.CIR-24-0011. Cancer Immunol Res. 2024. PMID: 38768394
Steroids in Immune Checkpoint Inhibitor Myocarditis.
Palaskas NL, Siddiqui BA, Deswal A. Palaskas NL, et al. Among authors: siddiqui ba. JACC CardioOncol. 2024 Aug 6;6(5):800-803. doi: 10.1016/j.jaccao.2024.07.002. eCollection 2024 Oct. JACC CardioOncol. 2024. PMID: 39479336 Free PMC article. No abstract available.
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.
Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, Streiff MB, Garcia DA, Liebman HA, Belani CP, O'Reilly EM, Patel JN, Yimer HA, Wildgoose P, Burton P, Vijapurkar U, Kaul S, Eikelboom J, McBane R, Bauer KA, Kuderer NM, Lyman GH; CASSINI Investigators. Khorana AA, et al. N Engl J Med. 2019 Feb 21;380(8):720-728. doi: 10.1056/NEJMoa1814630. N Engl J Med. 2019. PMID: 30786186 Clinical Trial.
292 results